S 2650, the DOCTORS Act, requires state health agencies to report unused J-visa waivers allowing foreign doctors to stay in the U.S. after training. Starting in 2026, the Secretary of State will redistribute 1/3 of these unused waivers as "supplemental waivers" to states that used at least 30 waivers the previous year. Ten percent of these supplemental waivers must be allocated to medical facilities serving patients in medically underserved communities. The bill directly affects state health agencies managing visa waivers and aims to increase access to healthcare in underserved areas by reducing wasted visa slots.
HCONRES 78 is a symbolic resolution designating March 10, 2026, as "Abortion Provider Appreciation Day" to honor abortion providers and staff. It recognizes their work amid rising violence, clinic closures, and abortion restrictions following the Dobbs decision, citing threats and challenges faced by providers. The resolution expresses congressional support for providers' safety and access to abortion care, condemning policies that restrict access. It does not create new laws or alter existing policies - it solely affirms Congress’s stance through a symbolic gesture. This is a procedural resolution focused on recognition, not policy change.
This bill extends the temporary enhanced premium tax credits for health insurance under the Affordable Care Act through 2028, instead of ending in 2026. It directly affects individuals purchasing health insurance through state or federal marketplaces who qualify for these credits based on income (up to 400% of the federal poverty level). The key change updates specific dates in tax law to align the credit period with 2028, while maintaining the same income eligibility rules. The extension applies to tax years beginning after December 31, 2025.
S 2035, the "Protect IVF Act," establishes federal rights to access and provide fertility treatment, including IVF, under widely accepted medical standards defined by the American Society for Reproductive Medicine. It directly affects patients seeking fertility care, health care providers offering IVF services, health insurance issuers covering such care, and manufacturers of fertility-related drugs or devices. The bill preempts state laws that restrict IVF access in ways inconsistent with medical standards - such as mandating unnecessary procedures, limiting telemedicine, or imposing discriminatory barriers - and allows federal court enforcement against violating state actions. This focuses on protecting existing access rather than creating new benefits or altering insurance coverage requirements.
HR 2062 would allow taxpayers to deduct membership fees and medical expenses paid through health care sharing ministries (HCSMs) as medical expenses on their federal tax returns, similar to other health costs. It specifically adds HCSM membership to the list of deductible medical expenses under Internal Revenue Code Section 213(d)(1) and clarifies that HCSMs are not treated as health insurance under Section 7702C. This change directly affects individuals enrolled in HCSMs, which are faith-based or community-based cost-sharing groups operating outside traditional insurance. The bill would take effect for tax years beginning after December 31, 2025.
The Closing the Contraception Coverage Gap Act requires Medicare Part B, Part C, and Part D to cover all FDA-approved contraceptive items and services at no cost-sharing starting January 1, 2027. This includes not just contraceptive methods themselves but also related clinical services like counseling, examinations, device insertion, and follow-up care. The bill ensures dual-eligible Medicare and Medicaid beneficiaries receive contraceptive coverage that matches Medicaid's comprehensiveness. It also mandates two studies on contraceptive coverage gaps, with reports to Congress within 1-2 years.
This bill reclassifies pharmacy benefit managers (PBMs) as fiduciaries under federal law, requiring them to act in the best interest of group health plans they serve. It mandates PBMs to disclose all compensation sources (including rebates and fees) and prohibits them from shielding themselves from liability for breaches of duty. The law directly affects PBMs, employers offering health plans, and health insurers that use PBM services. Key provisions include new transparency rules, clarifying that PBMs cannot be the "responsible fiduciary" for disclosure purposes, and banning contracts that exempt PBMs from accountability.
The MORE Savings Act eliminates copays and deductibles for opioid treatment under Medicare, private health plans, and Medicaid. It requires Medicare beneficiaries to have no out-of-pocket costs for opioid treatment drugs, behavioral health services, and recovery support (like peer counseling and transportation). Private health plans must cover these services without cost-sharing starting in 2027, and Medicaid states get a 90% federal match for medication-assisted treatment. The bill directly affects Medicare beneficiaries, private insurance enrollees, and Medicaid recipients seeking opioid use disorder treatment.
This bill modifies how Medicare calculates rebates for certain drugs to potentially lower costs for beneficiaries. It changes the reference year for rebate calculations from 2021 back to 2016 for both Medicare Part B (outpatient drugs) and Part D (prescription drug coverage) programs. The bill also adjusts how drug units are counted for rebates, excluding units paid for through state Medicaid programs or other existing rebate programs. These changes apply to Part B rebates starting January 2026 and Part D rebates starting October 2025. The policy directly affects drug manufacturers who pay Medicare rebates and impacts Medicare beneficiaries through potential cost reductions in covered drugs.
HR 6575, the CommonGround for Affordable Health Care Act, extends enhanced premium tax credits for health insurance through 2026, directly benefiting millions of lower and middle-income Americans purchasing coverage through the ACA marketplace. The bill modifies income thresholds for premium subsidies, creating new income tiers that maintain or increase financial assistance for households earning up to 1,000% of the poverty level. It includes provisions to prevent fraud in health insurance exchanges by imposing civil penalties on agents and brokers who provide false information, and requires transparency in pharmacy benefit manager contracts to improve drug pricing accountability. The legislation also extends the annual open enrollment period for health insurance exchanges for the 2026 plan year, allowing more time for people to enroll or change coverage.